MBI International and Michigan State University have entered into a new collaborative arrangement, under which promising bio-based technologies will be accelerated from the laboratory to commercial deployment. The agreement combines MSU's research expertise with MBI's derisking process and bioprocessing facilities to quickly and efficiently demonstrate the market-readiness of new technologies. Intellectual property arising from the collaboration will be bundled, providing industrial partners with both a more valuable technology package and a streamlined process for accessing the technology. Under the collaboration, MBI's multi-disciplinary technical and business experts will work closely with MSU faculty and technology transfer specialists to identify promising technologies arising from MSU research. Selected technologies will be derisked by MBI. Derisking is a term coined by MBI to denote a disciplined, stage-gated innovation process designed to rapidly demonstrate commercial viability at a meaningful pilot scale.

Michigan State University has appointed Richard R. Neubig as professor and chairperson of the Department of Pharmacology and Toxicology, a department affiliated with the colleges of Osteopathic Medicine, Human Medicine and Veterinary Medicine. Neubig will begin his work at MSU July 1. Dr. Neubig brings to MSU stellar credentials in pharmacological research.

Michigan State University Presents at The Americas Lodging Investment Summit, Jan-22-2013 10:45 AM. Venue: JW Marriott at LA LIVE, Los Angeles, California, United States. Speakers: A.J. Singh, Associate Professor.